Literature DB >> 3002607

Growth factors and cancer.

A S Goustin, E B Leof, G D Shipley, H L Moses.   

Abstract

Growth factors, defined as polypeptides that stimulate cell proliferation, are major growth-regulatory molecules for cells in culture and probably also for cells in vivo. Nontransformed cells show an absolute requirement for growth factors for proliferation in culture and generally more than one growth factor is required. Under usual culture conditions, growth factors are more rapidly depleted than other media components and thus become rate limiting for proliferation. The loss of or decreased requirement for specific growth factors is a common occurrence in neoplastically transformed cells and may lead to a growth advantage, a cardinal feature of cancer cells. Recent work with transforming growth factors, the platelet-derived growth factor, and oncogenes has produced some insight into the mechanisms through which alterations in growth factor-receptor-response pathways could lead to a growth advantage. Evidence has been derived for autocrine secretion in which the cell produces its own growth factor. Many transformed mesenchymal cells produce PDGF (the product of the c-sis proto-oncogene) and certain transformed cells both produce and respond in a growth-stimulatory manner to TGF beta. With TGF beta, which is a growth inhibitor for certain epithelial and other cell types, the loss of the normal inhibitory response in transformed cells could have the same result as the activation of a growth-stimulatory response. Two proto-oncogenes, erbB and fms, encode growth factor receptors. In the erbB case, the viral erbB aberrant receptor produced is truncated and appears to be constitutively activated without the need for a growth factor. Recent studies suggest that the p21 product of the ras oncogene may be an obligatory intermediate in transducing the growth factor signal. Activation of ras may, therefore, activate the growth factor pathway without the need for either a growth factor or its receptor. The transcription of myc and fos is induced by growth factor stimulation of quiescent cells. The protein products of both are nuclear associated and conceivably could be involved in regulating other genes important in the control of cell proliferation. Activation or inappropriate expression of either myc or fos could produce the same end result as stimulation of a growth factor pathway leading to a growth advantage. Study of the molecular mechanism(s) of growth factor action has just begun. The excitement and attention focused on cellular oncogenes in recent years is now turning toward growth factors, not only as they concern the control of normal cell growth but also the involvement of growth factor-initiated pathways in the etiology of cancer.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3002607

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  170 in total

1.  Controlling tumor-derived and vascular endothelial cell growth: role of the 4Ff2 cell surface antigen.

Authors:  M Papetti; I M Herman
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Epithelins 1 and 2: isolation and characterization of two cysteine-rich growth-modulating proteins.

Authors:  M Shoyab; V L McDonald; C Byles; G J Todaro; G D Plowman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

3.  Effect on the canine Eck fistula liver of intraportal TGF-beta alone or with hepatic growth factors.

Authors:  A Francavilla; A Azzarone; G Carrieri; C Scotti-Foglieni; Q H Zeng; U Cillo; K Porter; T E Starzl
Journal:  Hepatology       Date:  1992-11       Impact factor: 17.425

Review 4.  Biochemical study of cyst fluid in human breast cystic disease: a review.

Authors:  C L Enriori; J E Novelli; M del C Cremona; R J Hirsig; P J Enriori
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

5.  Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.

Authors:  M Alimandi; L M Wang; D Bottaro; C C Lee; A Kuo; M Frankel; P Fedi; C Tang; M Lippman; J H Pierce
Journal:  EMBO J       Date:  1997-09-15       Impact factor: 11.598

6.  Antibody to type I insulinlike growth factor receptor inhibits growth of Wilms' tumor in culture and in athymic mice.

Authors:  T Gansler; R Furlanetto; T S Gramling; K A Robinson; N Blocker; M G Buse; D A Sens; A J Garvin
Journal:  Am J Pathol       Date:  1989-12       Impact factor: 4.307

7.  Expression of nerve growth factor and brain-derived neurotrophic factor in astrocytomas.

Authors:  Ting-Ting Liu; Hao Wang; Feng Juan Wang; Yu Feng Xi; Li Hua Chen
Journal:  Oncol Lett       Date:  2017-11-02       Impact factor: 2.967

Review 8.  Signal transduction pathways: new targets in oncology.

Authors:  R K Sweeb; J H Beijnen
Journal:  Pharm World Sci       Date:  1993-12-17

9.  Characterization and growth factor stimulation of L-arginine transport in a human colon cancer cell line.

Authors:  J C Cendan; W W Souba; E M Copeland; D S Lind
Journal:  Ann Surg Oncol       Date:  1995-05       Impact factor: 5.344

10.  Effect of medroxyprogesterone acetate (MPA) and serum factors on cell proliferation in primary cultures of an MPA-induced mammary adenocarcinoma.

Authors:  G Dran; I A Luthy; A A Molinolo; F Montecchia; E H Charreau; C D Pasqualini; C Lanari
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.